- Home
- OBIO vs PFO Comparison
OBIO vs PFO Comparison
Compare OBIO & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- PFO
- Stock Information
- Founded
- OBIO 2017
- PFO 1991
- Country
- OBIO United States
- PFO United States
- Employees
- OBIO N/A
- PFO N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- PFO Finance Companies
- Sector
- OBIO Health Care
- PFO Finance
- Exchange
- OBIO Nasdaq
- PFO Nasdaq
- Market Cap
- OBIO 147.8M
- PFO 121.4M
- IPO Year
- OBIO N/A
- PFO N/A
- Fundamental
- Price
- OBIO $2.75
- PFO $9.43
- Analyst Decision
- OBIO Strong Buy
- PFO
- Analyst Count
- OBIO 4
- PFO 0
- Target Price
- OBIO $14.00
- PFO N/A
- AVG Volume (30 Days)
- OBIO 339.4K
- PFO 31.8K
- Earning Date
- OBIO 08-12-2025
- PFO 01-01-0001
- Dividend Yield
- OBIO N/A
- PFO 6.51%
- EPS Growth
- OBIO N/A
- PFO N/A
- EPS
- OBIO N/A
- PFO N/A
- Revenue
- OBIO $2,944,000.00
- PFO N/A
- Revenue This Year
- OBIO $19.83
- PFO N/A
- Revenue Next Year
- OBIO $12.53
- PFO N/A
- P/E Ratio
- OBIO N/A
- PFO N/A
- Revenue Growth
- OBIO 41.61
- PFO N/A
- 52 Week Low
- OBIO $2.37
- PFO $6.90
- 52 Week High
- OBIO $6.50
- PFO $8.51
- Technical
- Relative Strength Index (RSI)
- OBIO 50.09
- PFO 71.21
- Support Level
- OBIO $2.65
- PFO $9.27
- Resistance Level
- OBIO $3.08
- PFO $9.31
- Average True Range (ATR)
- OBIO 0.16
- PFO 0.05
- MACD
- OBIO 0.03
- PFO 0.01
- Stochastic Oscillator
- OBIO 52.86
- PFO 98.08
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.